Galapagos delivers candidate drug in osteoarthritis alliance with Servier

25-Jul-2012 - Belgium

Galapagos NV announced that it has identified the first pre-clinical candidate compound in its osteoarthritis alliance with Servier.  The compound inhibits a novel mechanism of action discovered by Galapagos.  This achievement triggered an undisclosed milestone payment to Galapagos.

In July 2010, Servier and Galapagos announced their alliance to develop new oral medicines for the treatment of osteoarthritis (OA).  Galapagos is responsible for the discovery and development of new candidate drugs, and Servier has an exclusive option to license these after the completion of Phase I clinical trials.  Galapagos retains exclusive US commercialization rights to all compounds discovered.

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance